Reuters
20 Jul 2026, 00:16 UTC · 19h ago
Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
20 Jul 2026, 00:16 UTC · 19h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Samsung Biologics is launching an all-cash bid of 1.46 billion Swiss francs ($1.81 billion) to acquire PolyPeptide. — A multi-billion dollar acquisition indicates aggressive expansion into new drugmaking capabilities, typically viewed positively for the acquirer's long-term growth and the target's valuation.
+0.60Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
[a_to_b] Samsung Biologics is launching an all-cash bid to acquire PolyPeptide.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
GlobeNewsWire
2h ago
